Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

ne technology) and NRP290 (a pain product acquired with the New River Pharmaceuticals Inc. ("New river") acquisition).

Business Highlights

- SPD754 (Apricitabine) - HIV - Shire licensed its residual rights (for the US and Canada) for the investigational HIV compound to Avexa Limited ("Avexa") on January 23, 2007. In return Shire received an upfront cash payment of $10 million and Avexa shares valued at approximately $3 million.

- In April 2007 Shire completed the acquisition of New River by way of a short-form merger for $64 per share, or approximately $2.6 billion, partly funded by a private equity placing of $0.9 billion in February 2007.

- In May 2007 Shire issued $1.1 billion principal amount of convertible bonds due 2014. The proceeds of the bonds were used by Shire to repay borrowings under its bank facilities previously drawn to partially fund the acquisition of New River.

- Product divestments - In December 2007 Shire completed the sale of a portfolio of non-core products, including SOLARAZE(R) and VANIQA(R) to Laboratorios Almirall S.A. ("Almirall") for a cash consideration of $209.6 million, net of costs of $2.2 million. During the year Shire also received cash consideration of $24.8 million from the sale of other non-core products.

- Legal settlements

- In October 2007, all parties to the 2003 Transkaryotic Therapies, Inc. class action securities lawsuit relating to REPLAGAL reached an agreement in principle to resolve the matter, subject to court approval, for $50 million. Shire will contribute $27 million toward the settlement (recognized in Q3 2007 within Selling, General and Administration ("SG&A") costs) and its insurance companies will contribute the remaining $23 million.

- In November 2007 Shire agreed to pay Applied Research Systems Holding N.V and Serono S.A. ("Serono") $12 million for a fully-paid, worldwide, non-exclusive license to Serono's patents related to gene-activation, including t
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... ZIONA, Israel , June 18, 2013 ... complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, ... announced today that the company has been granted a ... indicated in the US and Europe ... US Patent number 8,410,176 B2 is titled Intermediate Compounds ...
(Date:6/18/2013)... Toronto, Canada (PRWEB) June 18, 2013 ... FDA oversight of pharmaceutical advertising and promotion, and ... , Viewers will learn how to apply these ... enforcement examples:, ,     The fundamentals on ... advertising and promotional labeling ,     Assessing traditional ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/4b8vj2/injectable_drug ) has announced the addition of ... Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables ... Free & Auto Injectors] & Therapeutics [Diabetes ... report to their offering. ...
(Date:6/18/2013)... 18, 2013 As a leading ... proudly announces the release of their infographic - ... ". , MeMD's goal was to leverage an ... Health 2.0, Health 3.0 and mHealth.The infographic features ... medical care and the fitness industry in unimaginable ...
Breaking Biology Technology:Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3MeMD, Inc Releases Infographic Featuring the Top Eight Technologies that are Revolutionizing Health and Fitness Today 2
... Cedara Software , a Merge Healthcare developer ... with Ft. Lauderdale-based dental imaging company, i-Dent Imaging ... agreement, Cedara will be an exclusive global channel for ... contacts to promote and market this technology to customers ...
... some buzz rustling around the biz about how gaming is going ... UW-System Advanced Distributed Learning Co-Lab are doing some really ... ,Guess what? Gaming is just the tip of an iceberg big ... shop floor to the boardroom. , ,This is a great ...
... receive a $500,000 grant from the Department of Commerce ... Gateway Manufacturing Technology Center in Eau Claire. Nanotechnology is ... of the atom. , ,"Through this project, we are ... expand, and reach its full potential," said Gov. Jim ...
Cached Biology Technology:Just in time for Christmas: Retail IT. 2Just in time for Christmas: Retail IT. 3
(Date:6/19/2013)... 2013 A decade-long JDRF-funded study led by ... Mnchen, Germany, is providing a deeper understanding of ... developing type 1 diabetes (T1D), highlighting the importance ... disease. The study, "Seroconversion to Multiple Islet Autoantibodies ... was published today in The Journal of ...
(Date:6/19/2013)... NEW YORK , June 19, 2013  New ... #8,461,981 by the United States Patent and Trademark Office ... security systems that reflect whether guards have been injured, ... of an extensive portfolio under the Intellectual Properties Agreements ... Lisa Pamintuan , President of New ...
(Date:6/19/2013)... 19, 2013 Elsevier, a world-leading provider of scientific, ... to announce the launch of a new open access ... of GeoResJ , Elsevier,s earth and planetary science ... The journal aims to provide a forum for rapid ... field. The journal will be co-edited by six Executive ...
Breaking Biology News(10 mins):New data on islet autoantibodies in young children defines early type 1 diabetes development 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4
... wastewater and generates electricity can also remove 90 percent of ... team of researchers from China and the U.S. Clean ... resource in some parts of the world. Its availability in ... desalinate water using either a reverse osmosis process -- one ...
... global warming from 53 million to 47 million years ago ... western North America, researchers from three research museums report in ... of the National Academy of Sciences . "Today, ... few antelope and deer are all you see," said lead ...
... aim to slow global warming through the use of ... But new research shows that the use of geoengineering ... In a symposium at the Ecological Society of America,s ... that it is potentially dangerous at the global scale, ...
Cached Biology News:Wastewater produces electricity and desalinates water 2Wastewater produces electricity and desalinates water 3Climate-caused biodiversity booms and busts in ancient plants and mammals 2Symposium to discuss geoengineering to fight climate change at the ESA Annual Meeting 2
... Peptide Antigen Design , Customer Peptide Synthesis , ... above 90%, 20 mg will be returned to customer conjugation of ... , Maintenance 102 days/each , ... x5 /each , Test bleed (app. 5 ...
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
Biology Products: